Top

Published in:

01-02-2009 | Letter to the Editor

MDA-MB-435 cells are from melanoma, not from breast cancer

Author: Marc Lacroix

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2009

Abstract

For years, MDA-MB-435 cells have been widely but erroneously used as breast cancer cells with aggressive behaviour. Recent data show that they are in fact melanoma cells. However, many scientists are still unaware of this “new” identity.

Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA, Lavasanifar A (2008) Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol Feb 20 [Epub ahead of print]. doi:10.1007/s00280-008-0704-z

Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R (2008) Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol Mar 19 [Epub ahead of print]. doi:10.1007/s00280-008-0727-5

Lacroix M (2008) Persistent use of “false” cell lines. Int J Cancer 122:1–4PubMedCrossRef

Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227–235PubMedCrossRef

Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294–299PubMedCrossRef

Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D (2004) Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64:3479–3485PubMedCrossRef

Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13–19PubMedCrossRef

Title: MDA-MB-435 cells are from melanoma, not from breast cancer
Author: Marc Lacroix
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0776-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand

Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma

A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias

Keynote webinar | Spotlight on antibody–drug conjugates in cancer